이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

FDA approves Hugel‘s botulinum toxin Letybo

Collected: 2024.03.05

Distributed: 2024.03.06

Source: Go Direct

[Courtesy of Hugel Inc.]

The United States’ Food and Drug Administration (FDA) recently approved Letybo (letibotulinumtoxinA-wlbg), a blockbuster botulinum toxin product developed by Hugel Inc., for the treatment of moderate to severe glabellar lines in adults.

Letybo is supplied in a single-dose vial containing either 50 units/vial or 100 units/vial.

With the FDA approval in hand, Hugel is now the first South Korean pharmaceutical company to sell its products in the United States, China, and Europe, all three of which have the biggest market shares in the botulinum toxin industry globally.

The United States is the world’s biggest botulinum toxin market, with a market share of over 50 percent. Multiple surveys found that the U.S. market will likely double in size to hit sales of 6.36 trillion won ($4.7 billion) by 2031.

By Kim Jee-hee and Han Yubin

List

Previous: LG Electronics to enhance global call center capabilities

Next: Hanwha Ocean inks MOU for supply of LNG carriers